Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 500 citing articles:

Psoriatic Arthritis
Christopher T. Ritchlin, Robert A. Colbert, Dafna D. Gladman
New England Journal of Medicine (2017) Vol. 376, Iss. 10, pp. 957-970
Closed Access | Times Cited: 1088
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 700.1-712
Open Access | Times Cited: 828
Psoriasis pathogenesis and the development of novel targeted immune therapies
Jason E. Hawkes, Tom C. Chan, James G. Krueger
Journal of Allergy and Clinical Immunology (2017) Vol. 140, Iss. 3, pp. 645-653
Open Access | Times Cited: 797
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt, Andrea Chiricozzi
Clinical Reviews in Allergy & Immunology (2018) Vol. 55, Iss. 3, pp. 379-390
Open Access | Times Cited: 583
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
Philip J. Mease, Stephen Hall, Oliver FitzGerald, et al.
New England Journal of Medicine (2017) Vol. 377, Iss. 16, pp. 1537-1550
Open Access | Times Cited: 506
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
Jason E. Hawkes, Bernice Y. Yan, Tom C. Chan, et al.
The Journal of Immunology (2018) Vol. 201, Iss. 6, pp. 1605-1613
Open Access | Times Cited: 477
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, et al.
Arthritis Care & Research (2018) Vol. 71, Iss. 1, pp. 2-29
Open Access | Times Cited: 435
Interleukin 17 is a chief orchestrator of immunity
Marc Veldhoen
Nature Immunology (2017) Vol. 18, Iss. 6, pp. 612-621
Closed Access | Times Cited: 415
Enthesitis: from pathophysiology to treatment
Georg Schett, Rik Lories, Maria Antonietta DʼAgostino, et al.
Nature Reviews Rheumatology (2017) Vol. 13, Iss. 12, pp. 731-741
Closed Access | Times Cited: 412
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, et al.
Arthritis & Rheumatology (2018) Vol. 71, Iss. 1, pp. 5-32
Open Access | Times Cited: 395
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash, Bruce Kirkham, Masato Okada, et al.
The Lancet (2017) Vol. 389, Iss. 10086, pp. 2317-2327
Closed Access | Times Cited: 353
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?
Kenneth F. Baker, John D. Isaacs
Annals of the Rheumatic Diseases (2017) Vol. 77, Iss. 2, pp. 175-187
Closed Access | Times Cited: 337
Inflammatory mechanisms in tendinopathy – towards translation
Neal L. Millar, George A.C. Murrell, Iain B. McInnes
Nature Reviews Rheumatology (2017) Vol. 13, Iss. 2, pp. 110-122
Closed Access | Times Cited: 329
Psoriasis: Which therapy for which patient
Shivani B. Kaushik, Mark Lebwohl
Journal of the American Academy of Dermatology (2018) Vol. 80, Iss. 1, pp. 27-40
Closed Access | Times Cited: 318
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados, et al.
The Lancet (2018) Vol. 392, Iss. 10163, pp. 2441-2451
Open Access | Times Cited: 303
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2017)
Open Access | Times Cited: 300
Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition
Jose U. Scher, Alexis Ogdie, Joseph F. Merola, et al.
Nature Reviews Rheumatology (2019) Vol. 15, Iss. 3, pp. 153-166
Closed Access | Times Cited: 288
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Philip J. Mease, Josef S Smolen, Frank Behrens, et al.
Annals of the Rheumatic Diseases (2019) Vol. 79, Iss. 1, pp. 123-131
Open Access | Times Cited: 247
Ankylosing spondylitis: an autoimmune or autoinflammatory disease?
Daniele Mauro, Ranjeny Thomas, Giuliana Guggino, et al.
Nature Reviews Rheumatology (2021) Vol. 17, Iss. 7, pp. 387-404
Closed Access | Times Cited: 225
The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Taoming Liu, Sheng Li, Shuni Ying, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 221
Old and New Biological Therapies for Psoriasis
Kirsten Rønholt, Lars Iversen
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 11, pp. 2297-2297
Open Access | Times Cited: 217
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
Sophie Glatt, Dominique Baeten, Terry Baker, et al.
Annals of the Rheumatic Diseases (2017) Vol. 77, Iss. 4, pp. 523-532
Open Access | Times Cited: 217
Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP
Hideki Fujita, Tadashi Terui, Koremasa Hayama, et al.
The Journal of Dermatology (2018) Vol. 45, Iss. 11, pp. 1235-1270
Open Access | Times Cited: 209
The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
Dennis McGonagle, Iain B. McInnes, Bruce Kirkham, et al.
Annals of the Rheumatic Diseases (2019) Vol. 78, Iss. 9, pp. 1167-1178
Open Access | Times Cited: 206
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Philip J. Mease, Apinya Lertratanakul, J. Anderson, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 3, pp. 312-320
Open Access | Times Cited: 194
Page 1 - Next Page

Scroll to top